By Stephen Neidle
The last word resource of knowledge at the layout of recent anticancer brokers, emphasising small molecules, this latest paintings covers contemporary awesome successes due to the human genome and melanoma genomics tasks. those advances have supplied details on ambitions fascinated by particular cancers which are resulting in potent drugs for a minimum of a number of the universal sturdy tumours. distinct sections clarify the elemental underlying ideas of melanoma drug improvement and supply a realistic creation to fashionable equipment of drug layout. attractive to a huge viewers, this is often a very good reference for translational researchers attracted to melanoma biology and drugs in addition to scholars in pharmacy, pharmacology, or medicinal and organic chemistry, and clinicians taking oncology concepts.
Read Online or Download Cancer Drug Design and Discovery PDF
Similar oncology books
Because the Seventies, euthanasia has been a subject matter of continuous debate around the world. This ebook provides an in depth description of the talk in addition to a serious research of the main salient elements of euthanasia perform within the Netherlands. The authors argue that euthanasia may be understood inside a ancient context as a protest opposed to clinical energy.
This new quantity brings jointly the present considering in either research and administration of the melanoma sufferer. It provides a entire caseload as visible by way of the oncologist. those are universal but demanding real-life sufferer situations, which the authors get to the bottom of through drawing at the most recent released literature.
Melanoma stem cells have initially been pointed out in leukemia and later in numerous good tumor forms. they've got very diversified houses from the majority of the tumor as they divide even more slowly and feature very effective drug resistance mechanisms. present remedies may possibly principally spare melanoma stem cells.
- Cancer Sourcebook for Women, 4th edition (Health Reference Series)
- Perry's The Chemotherapy Source Book
- Medicinal Chemistry of Anticancer Drugs
- Mindfulness: A Kindly Approach to Being with Cancer
Additional info for Cancer Drug Design and Discovery
L. (2003). Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev. 17, 2998–3010. , Berdini, V. et al. (2007). Identification of novel inhibitors of protein kinase B using fragment-based lead discovery. J. Med. Chem. 50, 2293–2296. L. (2004). Stuart Schreiber: biology from a chemist’s perspective. Interview by Joanna Owens. Drug Discov. Today 9, 299–303. L. (2003). Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721–732. Shaffer, C. (2007). Next-generation sequencing outpaces expectations.
2004). Strategies to overcome resistance to targeted protein kinase inhibitors. Nat. Rev. Drug Discov. 3, 1001–1010. , Cox, C. et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949–954. , Graham, B. et al. (2007). A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera. J. Mol. Biol. 367, 882–894. , Steele, J. et al. (2005). Components of successful lead generation. Curr. Top. Med. Chem. 5, 421–439. A. G. (2007). Economics of new drug development. J. Clin.
Ligand efficiency: a useful metric for lead selection. Drug Discov. Today. 9, 430–431. R. et al. (2000). Functional discovery via a compendium of expression profiles. Cell 102, 109–126. B. and Workman, P. (2004). The combination of cytotoxic and molecularly targeted therapies – can it be done? Drug Discov. Today: Ther. Strat. 4, 445–454. W. S. (2006). Lessons from Phase III clinical trials on antiVEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3, 24–40. , Wishart, G. (2006). Medicinal chemistry of hERG optimizations: highlights and hang-ups.
Cancer Drug Design and Discovery by Stephen Neidle